Legalize / Ireland / Statutory Instrument

S.I. No. 353/2025 - Medicinal Products (Prescription and Control of Supply) (Amendment) Regulations 2025

Type Statutory Instrument

Publication 2025-07-25

Last updated 2026-09-08

State Repealed superseded text

Text As published

Source Irish Statute Book

articles 2

This is the act as published. Later amendments are not folded into the text below: each one is a separate act in this repository and an entry in this law's history.

1 amending act · 2026-09-08, S.I. No. 457/2026 - Medicinal Products (Prescription and Control of Supply) (Amendment) R…

Reform history JSON API

Notice of the making of this Statutory Instrument was published in

“Iris Oifigiúil” of 25th July, 2025.

I, JENNIFER CARROLL MACNEILL, Minister for Health, in exercise of the powers conferred on me by section 32 (as amended by section 16 of the Irish Medicines Board (Miscellaneous Provisions) Act 2006 (No. 3 of 2006) and section 9 of the Irish Medicines Board (Miscellaneous Provisions) Act 2024 (No. 4 of 2024)) of the Irish Medicines Board Act 1995 (No. 29 of 1995), hereby make the following regulations:

1.

(1) These Regulations may be cited as the Medicinal Products (Prescription and Control of Supply) (Amendment) Regulations 2025.

(2) The collective citation “the Medicinal Products (Prescription and Control of Supply) Regulations 2003 to 2025” includes these Regulations.

2.

In these Regulations –

“Principal Regulations” means the Medicinal Products (Prescription and Control of Supply) Regulations 2003 ( S.I. No. 540 of 2003 );

“Regulations of 2024” means the Medicinal Products (Prescription and Control of Supply) (Amendment) (No. 5) Regulations 2024 ( S.I. No. 582 of 2024 ).

The Twelfth Schedule (as amended by Regulation 3 of the Regulations of 2024) to the Principal Regulations is amended by inserting the following entry:

“

Medicinal product Form and presentation of product administered Route of administration Indication for which the medicinal product may be administered Dosage and conditions of administration

Column 1 Column 2 Column 3 Column 4 Column 5

Nirsevimab 50mg in 0.5mL pre-filled syringe; 100mg in 1mL pre-filled syringe. Intramuscular (IM) injection. Passive immunisation with nirsevimab of all infants who are born during the RSV season. Passive immunisation with nirsevimab of all *high-risk infants aged ≤12 months at the start of their first RSV season. Passive immunisation with nirsevimab of all infants who are aged ≤6 months at the start of the RSV season. Passive immunisation with nirsevimab of all ex-preterm infants under 24 months of age with Chronic Lung Disease in their second RSV season. In accordance with the summary of product characteristics and the relevant recommendations or guidelines issued by the National Immunisation Advisory Committee and accepted by the Minister for Health. Infants weight<5kg: A single dose of 50mg (0.5ml) administered intramuscularly. Infants weight≥5kg: A single dose of 100mg (1.0ml) administered intramuscularly. Children up to 24 months entering their second season: 200 mg given as 2 × 100 mg intramuscular injections.

”.


Medicinal product	Form and presentation of product administered	Route of administration	Indication for which the medicinal product may be administered	Dosage and conditions of administration
Column 1	Column 2	Column 3	Column 4	Column 5
Nirsevimab	50mg in 0.5mL pre-filled syringe; 100mg in 1mL pre-filled syringe.	Intramuscular (IM) injection.	Passive immunisation with nirsevimab of all infants who are born during the RSV season. Passive immunisation with nirsevimab of all *high-risk infants aged ≤12 months at the start of their first RSV season. Passive immunisation with nirsevimab of all infants who are aged ≤6 months at the start of the RSV season. Passive immunisation with nirsevimab of all ex-preterm infants under 24 months of age with Chronic Lung Disease in their second RSV season.	In accordance with the summary of product characteristics and the relevant recommendations or guidelines issued by the National Immunisation Advisory Committee and accepted by the Minister for Health. Infants weight<5kg: A single dose of 50mg (0.5ml) administered intramuscularly. Infants weight≥5kg: A single dose of 100mg (1.0ml) administered intramuscularly. Children up to 24 months entering their second season: 200 mg given as 2 × 100 mg intramuscular injections.

GIVEN under my Official Seal,

22 July, 2025.

JENNIFER CARROLL MACNEILL,

Minister for Health.

EXPLANATORY NOTE

(This note is not part of the Instrument and does not purport to be a legal interpretation.)

These Regulations amend the Medicinal Products (Prescription and Control of Supply) Regulations 2003.

The purpose of these Regulations is to update the schedule of medicinal products which may be supplied and administered pursuant to Regulation 4F of the Medicinal Products (Prescription and Control of Supply) Regulations 2003.

These Regulations may be cited as the Medicinal Products (Prescription and Control of Supply) (Amendment) Regulations 2025.

This document does not substitute the official text published in the Irish Statute Book. We accept no responsibility for any inaccuracies arising from the transcription of the original into this format.

This text is published under Irish Statute Book's own terms of reuse, not a Legalize or public-domain licence. Irish Statute Book
CC-BY 4.0 (Oireachtas Open Data PSI Licence)
Contains Irish Public Sector Information licensed under the Oireachtas (Houses of the Oireachtas) Open Data PSI Licence / Creative Commons Attribution 4.0 International, sourced from https://www.irishstatutebook.ie.